Welcome to UCB in Canada

Media & Funding

Media & Funding

Welcome to UCB's media room. This section offers resources for journalists, editors and other media professionals.

Blog

2023 – 2025 Economic and Sustainability Impact Report Launch
LEARN MORE
UCB Canda welcomes Jean-Christophe Tellier, global Chief Executive Officer and Chairman of the Executive Committee
LEARN MORE
Building Awareness and Hope for Patients with HS: A conversation with Dr. Hélène Veillette
LEARN MORE
Accelerating the Diagnosis of axSpA in Canada: How FASTRAX is Reshaping the Patient Journey
LEARN MORE

Latest News

BIMZELX® (bimekizumab injection) Receives Positive Reimbursement Recommendation from Canada’s Drug Agency for Hidradenitis Suppurativa

Following an examination of clinical evidence and stakeholder input, Canada’s Drug Agency (CDA-AMC) has recommendedBIMZELX® (bimekizumab injection) for reimbursement with conditions for patients with moderate to severe hidradenitis suppurativa. 

LEARN MORE
FASTRAX Canada Expands to Québec City, Strengthening National Efforts to Accelerate axSpA Diagnosis

UCB, a global biopharmaceutical company committed to improving the lives of people with severe diseases, announced the expansion of its FASTRAX Canada program into Québec City.

LEARN MORE
PrBIMZELX®(bimekizumab injection)

Receives Positive Reimbursement Recommendation from INESSS for Adults Living with Moderate to Severe Hidradenitis Suppurativa (HS)

LEARN MORE
CDA-AMC draft recommendation for PrBIMZELX®

UCB Canada remains dedicated to helping patients and working collaboratively with CDA-AMC following draft recommendation for PrBIMZELX® for hidradenitis suppurativa (HS)

LEARN MORE
PrBIMZELX®

Now Approved in Canada for the Treatment of Moderate to Severe Hidradenitis Suppurativa (HS)

LEARN MORE
UCB Canada Expands FASTRAX to Thunder Bay

Enhancing Axial Spondyloarthritis (axSpA) Patient Care in Northern Ontario

LEARN MORE

Media Relations for UCB Canada

If you are a member of the media and require further information about UCB Canada Inc. or its products, please contact: mediacanada@ucb.com.